Icosavax, UW IPD Spinout, Raises $100M Series B to Advance Computer-Designed Virus‑Like Particle Vaccines

Seattle biotech Icosavax, a University of Washington Institute for Protein Design spinout, raised $100 million in a Series B to develop computer-designed, virus-like particle vaccines including programs for COVID-19, RSV, and hMPV. The company, backed by investors led by RA Capital and supported by a $10 million Gates Foundation grant, has 17 employees and cites strong preclinical immune responses.

DDavid Baker IIcosavax UUniversity of Washington IInstitute for Protein Design